GET A PIECE OF TURN THERAPEUTICS

Survivor to Founder: CEO Turned Cure into Disruptive Biotech

A CEO who created his own cure, then bootstrapped his way to an up to +$85MM license deal, 16 patents, three FDA clearances, and 200,000+ patient uses. $15B+ market expansion in process.

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

$166,834.99 Raised

ABOUT

HEADQUARTERS
250 N. Westlake Blvd.
Westlake Village, CA 91362
WEBSITE
View Site
A CEO who created his own cure, then bootstrapped his way to an up to +$85MM license deal, 16 patents, three FDA clearances, and 200,000+ patient uses. $15B+ market expansion in process.

TEAM

Bradley Burnam

Bradley Burnam • Chief Executive Officer, Board Member & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn's flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn's first three FDA clearances solo before assembling a skilled team.

Read More

Dr. Neil Ghodadra, M.D.

Dr. Neil Ghodadra, M.D. • Chief Medical Officer & Board Member

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Read More

Abraham Chesed

Abraham Chesed • Board Member

Abraham (Avi) Chesed, an investor and entrepreneur with an aptitude for building and structuring brands, is a lifelong technologist, philanthropist, and mentor. He has founded and operated companies since graduating from the USC Marshall School of Business in 2003. Avi's thorough and professional focus has yielded substantial returns across multiple industries, recently in technology-focused startups. Avi has been a member of over a dozen boards and sits on five.

Read More

TERMS

Turn Therapeutics
Overview
PRICE PER SHARE
$11.26
DEADLINE
Apr. 1, 2026 at 6:59 AM UTC
VALUATION
$162.56M
FUNDING GOAL
$990.9 - $15M
Breakdown
MIN INVESTMENT
$495.44
MAX INVESTMENT
$14,999,997.74
MIN NUMBER OF SHARES OFFERED
88
MAX NUMBER OF SHARES OFFERED
1,332,149
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Bonus shares for this offering are capped at 20%

Voting Proxy

(a) The Subscriber hereby appoints the Chief Executive Officer of the Company (the “Chief Executive Officer”), or his or her successor as Chief Executive Officer, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution to assign this proxy to any officer or director, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Chief Executive Officer determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Chief Executive Officer for the accomplishment of the foregoing. See Offering Circular for complete information.

Investment Incentives & Bonuses*

Loyalty Bonus | 3% Bonus Shares

Investors who have previously, in a prior offering, invested in the Company, receive 3% Bonus Shares (the “Loyalty Bonus”), in addition to any StartEngine Venture Club Bonus shares, or Amount-Based Bonus shares, to which they are entitled to receive.

Amount-Based Bonus

Tier 1: Invest $5,000+ and receive 3% bonus shares.

Tier 2: Invest $10,000+ and receive 5% bonus shares.

Tier 3: Invest $25,000+ and receive 7% bonus shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.

The 10% StartEngine Venture Club Bonus

GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $11.26 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $1126. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus, provided that the maximum bonus shares granted to any investor shall not be greater than 20%.

ALL UPDATES

05.30.25

Kevin O’Leary Reacts to Turn’s Tech


“This solves a massive problem. If that happened to me, there would be no price that would matter.” - Kevin O’Leary

When Mr. Wonderful says “Let’s talk after this,” you know you’ve struck a chord. 

During the livestream, Kevin revealed his personal struggles with toenail fungus, calling it “extremely hard to cure.” He’s tried what's on the market. And he is not alone: over 10% of the planet struggles with toenail fungus. 

The science behind the tech is simple, yet powerful. Our patented, FDA-cleared technology is oil-based and proven to go where others can’t get: beneath the nail. 

Kevin O’Leary called Turn Therapeutics a company that could “create tremendous shareholder value,” with Bradley’s authentic mission, proven results, large markets, and the executional leadership to scale it. 

Kevin isn’t just impressed, he wants a sit down meeting to discuss getting involved with Turn Therapeutics. You can watch the full livestream here

Join us now before the momentum takes off.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  Kevin O’Leary is a paid spokesperson for StartEngine. See his 17(b) disclosure, here.  Kevin O'Leary is not endorsing Turn Therapeutics as an investment in this webinar; he is merely expressing his private opinion while interviewing companies funding on StartEngine.

05.27.25

Webinar: Going Public vs. Being Public


Going public is a milestone—but it shouldn’t be the finish line.

For companies that are truly prepared, a public listing can be a powerful step in a long-term growth plan. It’s a chance to scale impact, expand investor access, and create consistent value across broader markets. But when treated as the end goal, it can become a trap—stalling momentum instead of accelerating it. 

At Turn Therapeutics, we believe a company should earn the right to be public. To demonstrate that its ongoing programs are worthy of public market capital. To prioritize long-term plans, not just short-term hype. To prove that it will create value for its shareholders, not just flashy headlines. 

What You’ll Learn in This Webinar:

  • Why companies that treat public listings as endpoints often lose momentum.
  • The importance of consistent newsflow and communication.
  • The value of platform technologies for product pipelines.
  • Why having post-public financing in place before listing is so important.

🗓 Webinar Date: June 5, 2025

🕞 Time: 3:30PM ET

👉 Register for the Webinar Now

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.25.25

🇺🇲 This Memorial... Advancing Science for Troops

Today we take a moment to honor those who sacrificed their lives for us. 

At Turn Therapeutics, our mission is to create safe, effective medicines that challenge conventional limits. So having the opportunity to protect those that protect us brings deep excitement and motivation to our pursuit.

A Major Leap in Vaccine Science

We recently achieved a milestone in vaccine delivery: 100% recovery of live virus with our patented platform, even after 72 hours at room temperature. No refrigeration or freezers used. 

This could dramatically change vaccine access in combat zones, rural clinics, and disaster zones. Places where live vaccines with delicate storage requirements were deemed too hard to reach.

What’s Ahead

We are now commencing a study to determine maximum stability at both refrigerated and room temperature. From there, intranasal dosing studies will begin in an effort to develop a version that can be used in humans.

To those who served and sacrificed, thank you. 

We remember you in the mission we carry forward.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. 

05.25.25

Mr. Wonderful Livestream Recap & Replay

“Frankly, I think this is a very interesting deal, no question about it.”
-Kevin O’Leary

What made Mr. Wonderful (aka Kevin O’Leary) so excited about Turn Therapeutics?

"The best place to catch the waves in these kinds of companies is after they've proven one outcome, and then they're starting to multiply on that outcome... and you've proven you can get one to market. That's a very big deal" - Kevin O’Leary 

Key Highlights:

🌟 Kevin was thrilled with our toenail fungus formula after suffering it himself and finding no easy cures.

🌟 He recognized our massive market opportunity ($15B+) and affirmed Bradley’s ability to execute.

🌟 Mr. Wonderful sees a vision for global market distribution, with the goal of enhancing shareholder value over time.

🌟 By the end of the livestream, Kevin wanted to go beyond just a conversation.

Couldn’t join us live? Check out the replay below.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.23.25

We’re Going Live!

We're About to Start with Kevin O’Leary - Join Livestream Now!

Bradley Burnam built Turn Therapeutics after battling a drug-resistant infection and inventing his own cure. 

Hop on now as he joins Kevin O’Leary to share Turn’s journey from unlikely to unstoppable—and why he chose to invite everyone to own a piece of his life’s work. 

🗓 Friday, May 23 

⏰ 12PM ET

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.22.25

TOMORROW: Bradley Burnam & Kevin O’Leary

TOMORROW, you’ll hear a story that’s rare in biotech—and even rarer in healthcare.

Bradley Burnam didn’t come from a pharma dynasty. He started Turn Therapeutics in his garage, after battling his own drug-resistant infection and taking matters into his own hands. There, a safer, more effective drug delivery platform was invented. 3 FDA clearances and 17 patents later, investors are paying attention. 

This Friday, May 23 at 12pm ET, Bradley sits down with Kevin O’Leary (aka Mr. Wonderful) for a live conversation on what Turn has built and why investors, strategics, and media are watching closely. 

Here’s why investors are watching:

  • $2.3M+ raised in crowdfunding and $15M+ in total funding
  • 200,000+ human uses and zero reported adverse events
  • $85M investment commitment from a multibillion-dollar private equity fund

From wound care and eczema to cold-chain-free vaccines, this is the kind of biotech story that doesn’t come around often. And it’s just getting started.

See you at noon ET tomorrow.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.20.25

Reminder: Kevin O'Leary Livestream This Friday!

Tune in this Friday for a livestream you won’t want to miss. 

This week, Turn Therapeutics goes live with Kevin O’Leary to share why our multi-patented drug delivery platform, 3 FDA clearances, and major market segments are drawing big investor attention.

Founder & CEO Bradley Burnam will sit down with Mr. Wonderful to discuss:

  • The real-world impact of Turn’s innovations
  • Why our platform and pipeline is attracting serious institutional interest
  • What’s ahead in 2025 and beyond—and how investors can get in early

This isn’t a pitch—it’s a conversation about where healthcare is headed.

Event Details: 

🗓 Friday, May 23 

⏰ 12 pm ET


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.16.25

Additional $10M Secured: GEM Deal Expansion

We’re excited to announce an expansion of our capital partnership with global private equity fund, GEM.

This is an expansion of our existing $75M agreement with GEM, increasing their total committed capital to $85M. Under the updated agreement, Turn Therapeutics now has access to an additional up to $10 million in committed capital—available immediately upon going public

Why This Matters

✅ Up to $10M additional draw on the day of listing

🚫 No trading volume restrictions— funds are accessible regardless of market activity

🌟 Enhances investor confidence with a stronger cash position at debut

🏦 Demonstrates increased institutional backing, reinforcing the strength of our mission and model

Turn is not just thinking about today. We strategically are planning for needs at every phase of our future to ensure a healthy company with sufficient capital to achieve our intended goals. 

Thank you for your continued belief in what we’re building.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.15.25

Schedule Change: Kevin O’Leary Livestream


🚨 Schedule Update - Livestream Moved to May 23 @ 12pm ET

Join Kevin O’Leary (aka Mr. Wonderful) and Turn Therapeutics Founder & CEO Bradley Burnam for a livestream exploring the company's pioneering work, the vision driving its growth, and why investors are paying close attention to this disruptive force in the healthcare industry.

Turn Therapeutics is a biotechnology firm with FDA-cleared products, proprietary delivery platforms, and active engagement across multiple high-value therapeutic markets.

What You’ll Hear

🧬 The science behind Turn’s breakthrough drug delivery technology
🚀 What makes Turn Therapeutics a standout in modern medicine
📈 Why investors and media are paying attention

Bradley Burnam will also share Turn Therapeutics’ progress and why the company’s vision is gaining momentum across multiple health industries.

Ready to see what’s next for healthcare innovation? 

Tune in to the livestream May 23 @ 12pm ET.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

05.12.25

Major Milestone: 72H Vaccine Stability @ Room Temp


💉  Vaccine Delivery Breakthrough

Turn Therapeutics is poised to dramatically simplify the shipping, storage, and administration of vaccines, particularly in remote or low-resource settings.

After achieving 24 hour stability earlier this year, our newest study demonstrated 72 hours of stability with ZERO LOSS of viable vaccine at room temperature. Vaccines such as these typically last 4-6 hours at room temperature. This particular vaccine candidate is intended for troops and citizens in remote regions.

...a major leap in vaccine science. -Bradley Burnam, CEO

This milestone brings us closer to a world in which geography is no longer a barrier to life-saving medicines. 

✅  Simplified Shipping + Storage = Greater Vaccine Access

Our PermaFusion platform is flexible and scalable. This work brings us one step closer to the next generation of vaccine delivery

I wonder what will be next in our journey? 

To learn more, read the full press release on Business Wire by clicking below.


This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.

10%

Stack Venture Club & Rewards!

Members get an extra 10% shares in addition to rewards below!

Venture Club

Venture Club

Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

$5,000

Tier 1

Invest $5,000+ and receive 3% bonus shares.

$10,000

Tier 2

Invest $10,000+ and receive 5% bonus shares.

$25,000

Tier 3

Invest $25,000+ and receive 7% bonus shares.

JOIN THE DISCUSSION

0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

FAQ Timeline

WHY STARTENGINE?

Rewards Icon
REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

Lock Icon
SECURE

Your info is your info. We take pride in keeping it that way!

Ellipse Icon
DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

PREVIOUSLY CROWDFUNDED
$2,277,856.20
RAISED
$166,834.99
INVESTORS
70
MIN INVEST
$495.44
VALUATION
$162.56M

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.